|
|
 | | | |
- close
- close
- close
- close
This excerpt taken from the NVS 6-K filed Feb 9, 2010. Voltaren (USD 797 million, +1% lc, excluding OTC
sales), a treatment for various inflammation and pain conditions, no longer has
patent protection in key markets around the world, but has continued to
generate growth in regions such as Latin America, the Middle East, Africa and
Asia based on long-term trust in the brand.
This excerpt taken from the NVS 6-K filed Feb 9, 2009. Voltaren (USD 814 million, +3% lc, excluding OTC
sales), a treatment for inflammation and pain, no longer has patent protection
in key markets around the world, but has continued to generate consistent
growth in regions such as Latin America, the Middle East, Africa and Asia based
on long-term trust in the brand.
This excerpt taken from the NVS 6-K filed Feb 8, 2008. Voltaren (USD 747
million, +3% lc), a therapy for inflammation and pain, showed steady growth,
primarily in Latin America and Asia, based on long-term trust in the brand.
Patent protection for This excerpt taken from the NVS 6-K filed Jan 23, 2008. Voltaren
(USD 747 million, +3% lc), a therapy for inflammation and pain, showed steady
growth, primarily in Latin America and Asia, based on long-term trust in the
brand. Patent
14
protection for Voltaren in many key markets around the world has expired.
This excerpt taken from the NVS 6-K filed Feb 14, 2007. Voltaren is a branded pain relief drug sold primarily
in Europe where it is off patent in most countries. Novartis applies a
straight-line amortization period and the useful life is considered to end in
2011.
This excerpt taken from the NVS 20-F filed Jan 31, 2007. Voltaren Voltaren is a branded pain relief drug sold primarily in Europe where it is off patent in most countries. Novartis applies a straight-line amortization period and the useful life is considered to end in 2011. This excerpt taken from the NVS 6-K filed Apr 27, 2006. Voltaren in
Europe supported OTC. Animal Health delivered double-digit growth, with sales
spread more evenly over the year compared to prior years. Gerber delivered
mid-single-digit growth, while Medical Nutrition sales remained flat. CIBA
Vision sales were lower, impacted by ongoing remediation of a lens-care product
supply issue.
3
This excerpt taken from the NVS 6-K filed Feb 8, 2006. VOLTAREN Voltaren is a branded pain relief drug sold primarily in Europe where it is off patent in most countries. Novartis applies a straight-line amortization period and the useful life is considered to end in 2011. This excerpt taken from the NVS 20-F filed Jan 30, 2006. Voltaren Voltaren is a branded pain relief drug sold primarily in Europe where it is off patent in most countries. Novartis applies a straight-line amortization period and the useful life is considered to end in 2011. This excerpt taken from the NVS 6-K filed Feb 4, 2005. Voltaren Voltaren is off-patent in the US and many other countries. Novartis applies a straight-line amortization period and the useful life ends in 2011. This excerpt taken from the NVS 20-F filed Jan 28, 2005. Voltaren Voltaren is off-patent in the US and many other countries. Voltaren as a branded product has had approximately $600 million of sales outside of the US in each of the past three years. Novartis applies a straight-line amortization period and the useful life ends in 2011. | EXCERPTS ON THIS PAGE:
|
| |||||||
